RA
AKBA icon

Royce & Associates’s Akebia Therapeutics AKBA Stock Holding History

Royce & Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.4K Buy
+28,373
New +$39K ﹤0.01% 773
2018
Q2 		– Sell
-537
Closed -$5K – 1215
2018
Q1 		$5K Buy
537
+190
+55% +$2.66K ﹤0.01% 1239
2017
Q4 		$5K Buy
347
+100
+40% +$1.66K ﹤0.01% 1234
2017
Q3 		$5K Buy
+247
New +$3.8K ﹤0.01% 1225

Other funds holding AKBA

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM